|
Biotecnologia Aplicada
Elfos Scientiae
ISSN: 0684-4551
Vol. 14, Num. 1, 1997, pp. 41-42
|
Biotecnologia Aplicada 1997 Volume 14 No. 1, pp.41-42
AUTOIMMUNITY AND THE IMMUNOTHERAPY OF CANCER: IS THE INDUCTION OF
AUTOIMMUNITY A DESIRABLE STRATEGY IN CANCER IMMUNOTHERAPY?
Nicholas P Restifo
National Cancer Institute, NIH, Bethesda, MD, USA.
E-mail: restifo@helix.nih.gov
Code Number:BA97005
Size of Files:
Text: 5.9K
Graphics: No associated graphics files
Genes encoding antigens expressed by tumor cells that could potentially be
mployed in recombinant and synthetic anti-cancer vaccines can be grouped
into three categories. The first is non-germline genes (encoding sequences
that are not part of the "self" repertoire). Examples of such genes include
point mutations (mutant Ras, P53), fusion products (Bcr-abl) and viral
antigens (E6 and E7). The second category includes germline genes encoding
sequences that are not normally expressed in adult tissues. Examples here
are genes that are turned on exclusively during developement that are also
expressed by tumor cells as well as products of human endogenous
retroviruses (HERV). The third catogory is that of germline genes encoding
sequences that are expressed in particular tissue and tumor histologies.
Examples of these include overexpressed "normal" housekeeping genes, and
tissue differentiation Ags.
The three categories of potential tumor antigens are arranged in the order
of decreasing tumor specificity and increasing central and peripheral
tolerance. Thus, tissue differentiation antigens are not tumor specific
since they are expressed by normal tissues as well as tumor cells, and
issues of central and peripheral tolerance are likely to bedevil the
immunotherapist that attempts to use them as targets for immune
responses.
In this light, tissue differentiation antigens are the least attractive
category of those listed above. And yet, in the case of melanoma, we are
proposing to use melanocyte differentiation antigens (such as MART-1,
gp100, Tyrosinase, TRP-1, TRP-2 that are expressed by normal melanocytes
and by melanoma cells) as the best targets available for anti-tumor
immunotherapies based on recombinant and synthetic vaccines. On the face of
it, this seems like a very poor strategy.
There are five major elements that comprise the rationale for this
apparently counterintuitive decision: Melanocyte differentiation antigens
comprise the majority of the antigens that are recognized by anti-tumor T
lymphocytes that are capable of mediating regressions of metastatic
melanoma upon adoptive transfer to tumor bearing patients.
Vitiligo is associated with cancer regression in patients undergoing
immunotherapy with interleukin-2. In a prospective study of melanoma
patients treated with IL-2, none of the 27 nonresponding patients developed
vitiligo. Vitiligo was seen 11/43 (26 %) patients who experienced an
objective response to treatment. Presumably, vitiligo in the responders
results from the autoimmune destruction of normal melanocytes together with
the growing tumor. Since no other autoimmune manifestations were observed,
the most likely targets of these immune responses were melanocyte
differentiation antigens.
The problem of immune tolerance may be surmountable. Patients are obviously
not tolerant to all of the epitopes within a given protein. Indeed,
tolerance may be relevant for only the most highly presented epitopes.
The problem of lack of tumor specificity may have acceptable consequences
ie the destruction of normal tissue may be preferable to a metastatic
malignancy.
The strategy of targeting tissue differentiation antigens has application
to other malignancies arising from non-essential organs including but not
limited to prostate, ovarian and breast cancers.
Our current research efforts include the insertion of the genes encoding
tumor rejection antigens into a number of different recombinant viruses
including vaccinia viruses, fowlpox viruses, influenza A viruses and
adenoviruses. We have also constructed plasmids for naked DNA studies and
for studies involving the gene gun. We have taken this approach because we
have been encouraged by the observation that many attenuated, killed or
recombinant viruses or viral extracts can elicit powerful, specific and
life-long immunity (eg. smallpox, rabies, polio and hepatitis).
Furthermore, insertion of genes encoding antigens such as B-galactosidase
from Echerichia coli, chicken ovalbumin (OVA), and nucleoprotein
from Vesicular Stomatitis Virus (VSV) into experimental tumor cells elicits
very weak, if measurable, cellular immune responses against antigens. In
contrast, expression of these same experimental antigens by any number of
different recombinant viruses elicits powerful and specific cell-mediated
immune reactivities when measured in proliferation, cytokine release and
microcytotoxicity assays. Finally and most importantly, mice bearing model-
Ag expressing tumors can be treated successfully when they are inoculated
with viruses capable of mediating the expression of the same model
antigens.
We have just completed the cloning of the murine homologues to MART-
1/Melan-A, gp100, tyrosinase, TRP-1 and TRP-2 into a number of recombinant
vectors and we will employ the experimental murine tumor B16 to conduct
mouse experiments that paralell our human clinical studies. Some of the
mice that had recieved recombinant viruses expressing the murine versions
of the human tumor rejection antigens had experienced coat color changes
(from black to white) that were very similar to the vitiligo that we see in
some of our responding patients.
Copyright 1997 Elfos Scientiae
|